Mimedx Group Inc is a biotech company focused on the development and commercialization of regenerative medicine products, particularly those that utilize allogeneic placental tissues. The company aims to provide advanced solutions for wound care, surgical applications, and orthopedic treatments through its innovative therapies that promote healing and tissue regeneration. Mimedx's products are designed to support patient recovery by harnessing the natural properties of human placental tissues, thereby enhancing the body’s own healing processes. By combining scientific expertise with cutting-edge technology, Mimedx is committed to improving patient outcomes in various medical fields. Read More
According to the agreement, Summit Products Group will distribute Hydrelix, NovaForm, and G4Derm Plus, designed to complement MiMedx’s portfolio of leading surgical and wound products.
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
MIMEDX Group (MDXG) reports record Q2 2025 earnings, beating revenue and EPS estimates with $98.61M in sales and $0.10 EPS. Stock surges 11.8% post-announcement.
